Literature DB >> 3203929

Influence of antenatal screening on perinatal mortality caused by syphilis in Swaziland.

L F Guinness1, S Sibandze, E McGrath, A L Cornelis.   

Abstract

In a survey of 283 deliveries in Swaziland, active syphilis (positive results in the Treponema pallidum haemagglutination assay (TPHA) and the rapid plasma reagin (RPR) test) was found in 37 (13.1%) and possibly active infection (positive TPHA but negative RPR test results) in a further 87 (30.7%). The perinatal mortality of untreated mothers with active disease was 21.9% (7/32). The RPR test carried out antenatally by nurses had a sensitivity of 36% (13/36) and predictive accuracy of 48% (13/27). Awareness of this incidence of syphilis led to improved antenatal clinic measures and the prophylactic treatment of all newborn infants. More comprehensive serology is discussed and the prophylactic treatment of mothers considered. The need for health education aiming at safer sexual practices is of paramount importance in a society facing the arrival of the human immunodeficiency virus.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Biology; Demographic Factors; Developing Countries; Diseases; English Speaking Africa; Examinations And Diagnoses; Family And Household; Family Characteristics; Family Relationships; Fetal Death; Incidence; Infections; Laboratory Examinations And Diagnoses; Laboratory Procedures; Maternal Mortality; Measurement; Mortality; Mothers; Parents; Population; Population Dynamics; Reproductive Tract Infections; Research Methodology; Risk Factors; Sampling Studies; Screening; Sexually Transmitted Diseases; Southern Africa; Studies; Surveys; Swaziland; Syphilis; Treatment

Mesh:

Year:  1988        PMID: 3203929      PMCID: PMC1194246          DOI: 10.1136/sti.64.5.294

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  8 in total

1.  False-positive reactions in the rapid plasma reagin-card, fluorescent treponemal antibody-absorbed, and hemagglutination treponemal syphilis serology tests.

Authors:  C R Peter; M A Thompson; D L Wilson
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

2.  Treponema pallidum haemagglutination assay in the routine serodiagnosis of treponemal disease.

Authors:  P O'Neill; R W Warner; C S Nicol
Journal:  Br J Vener Dis       Date:  1973-10

3.  Observations on syphilis in Addis Ababa. 2. Prevalence and natural history.

Authors:  P S Friedman; D J Wright
Journal:  Br J Vener Dis       Date:  1977-10

4.  Serological determination of prevalence of congenital syphilis in two hospitals in Kenya.

Authors:  E M Wafula; N O Bwibo
Journal:  East Afr Med J       Date:  1982-11

5.  Genital infections in prenatal and family planning attendants in Swaziland.

Authors:  A Meheus; F Friedman; E Van Dyck; T Guyver
Journal:  East Afr Med J       Date:  1980-03

6.  Congenital syphilis in Lusaka--II. Incidence at birth and potential risk among hospital deliveries.

Authors:  C J Bhat; A V Ratnam; C Chintu; R C Mulenga
Journal:  East Afr Med J       Date:  1982-05

7.  Syphilis in Swaziland: a serological survey.

Authors:  J P Ursi; E van Dyck; C van Houtte; P Piot; J Colaert; M Dlamini; A Meheus
Journal:  Br J Vener Dis       Date:  1981-04

8.  Syphilis in pregnant women in Zambia.

Authors:  A V Ratnam; S N Din; S K Hira; G J Bhat; D S Wacha; A Rukmini; R C Mulenga
Journal:  Br J Vener Dis       Date:  1982-12
  8 in total
  10 in total

1.  The decentralization of syphilis screening for improved care in Jamaican public clinics. Collaborative Working Group on Decentralized Syphilis Screening.

Authors:  F M Behets; A Brathwaite; L Bennett; K G Douglas; G A Dallabetta; J P Figueroa
Journal:  Am J Public Health       Date:  1997-06       Impact factor: 9.308

2.  Criteria for early congenital syphilis--a perspective from Africa.

Authors:  M P Meyer
Journal:  Genitourin Med       Date:  1992-10

3.  Effect of a syphilis control programme on pregnancy outcome in Nairobi, Kenya.

Authors:  M Temmerman; P Gichangi; K Fonck; L Apers; P Claeys; L Van Renterghem; D Kiragu; G Karanja; J Ndinya-Achola; J Bwayo
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

Review 4.  Sexually transmitted diseases in children in developing countries.

Authors:  J Richens
Journal:  Genitourin Med       Date:  1994-08

5.  Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial.

Authors:  L Myer; D Wilkinson; C Lombard; K Zuma; K Rotchford; S S Abdool Karim
Journal:  Sex Transm Infect       Date:  2003-06       Impact factor: 3.519

Review 6.  Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.

Authors:  Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens
Journal:  BMC Pregnancy Childbirth       Date:  2010-02-23       Impact factor: 3.007

7.  Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy.

Authors:  Esme V Menezes; Mohammad Yawar Yakoob; Tanya Soomro; Rachel A Haws; Gary L Darmstadt; Zulfiqar A Bhutta
Journal:  BMC Pregnancy Childbirth       Date:  2009-05-07       Impact factor: 3.007

8.  High prevalence of sexually transmitted diseases in a rural area in Mozambique.

Authors:  B Vuylsteke; R Bastos; J Barreto; T Crucitti; E Folgosa; J Mondlane; T Dusauchoit; P Piot; M Laga
Journal:  Genitourin Med       Date:  1993-12

9.  Safety of benzathine penicillin for preventing congenital syphilis: a systematic review.

Authors:  Tais F Galvao; Marcus T Silva; Suzanne J Serruya; Lori M Newman; Jeffrey D Klausner; Mauricio G Pereira; Ricardo Fescina
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 10.  Lives Saved Tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality.

Authors:  Hannah Blencowe; Simon Cousens; Mary Kamb; Stuart Berman; Joy E Lawn
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.